Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Misato Hashizume

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Inflammation and Regeneration|October 7, 2020
Outlook of IL-6 signaling blockade for COVID-19 pneumoniaMisato Hashizume
Biochemical and Biophysical Research Communications|November 10, 2010
High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1Misato Hashizume, Masahiko Mihara
Endocrine, Metabolic & Immune Disorders Drug Targets|March 17, 2015
IL-6 as a target in inflammationMisato Hashizume, Yoshiyuki Ohsugi
Arthritis|November 3, 2011
The roles of interleukin-6 in the pathogenesis of rheumatoid arthritisMisato Hashizume, Masahiko Mihara
Rheumatology International|September 20, 2008
Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signalingMisato Hashizume, Masahiko Mihara
Cytokine|March 23, 2012
Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptorsMisato Hashizume, Masahiko Mihara
European Journal of Pharmacology|June 12, 2012
Blockade of IL-6 and TNF-α inhibited oxLDL-induced production of MCP-1 via scavenger receptor inductionMisato Hashizume, Masahiko Mihara
Rheumatology International|July 27, 2010
IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritisHiroto Yoshida, Misato Hashizume, Masahiko Mihara
Rheumatology International|May 18, 2010
Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 miceHiroto Yoshida, Misato Hashizume, Miho Suzuki, et al.
Cytokine|February 5, 2011
IL-6 plays an essential role in neutrophilia under inflammationMisato Hashizume, Yoshinobu Higuchi, Yasushi Uchiyama, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Inflammation and Regeneration|October 7, 2020
Outlook of IL-6 signaling blockade for COVID-19 pneumoniaMisato Hashizume
Biochemical and Biophysical Research Communications|November 10, 2010
High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1Misato Hashizume, Masahiko Mihara
Endocrine, Metabolic & Immune Disorders Drug Targets|March 17, 2015
IL-6 as a target in inflammationMisato Hashizume, Yoshiyuki Ohsugi
Arthritis|November 3, 2011
The roles of interleukin-6 in the pathogenesis of rheumatoid arthritisMisato Hashizume, Masahiko Mihara
Rheumatology International|September 20, 2008
Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signalingMisato Hashizume, Masahiko Mihara
Cytokine|March 23, 2012
Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptorsMisato Hashizume, Masahiko Mihara
European Journal of Pharmacology|June 12, 2012
Blockade of IL-6 and TNF-α inhibited oxLDL-induced production of MCP-1 via scavenger receptor inductionMisato Hashizume, Masahiko Mihara
Rheumatology International|July 27, 2010
IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritisHiroto Yoshida, Misato Hashizume, Masahiko Mihara
Rheumatology International|May 18, 2010
Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 miceHiroto Yoshida, Misato Hashizume, Miho Suzuki, et al.
Cytokine|February 5, 2011
IL-6 plays an essential role in neutrophilia under inflammationMisato Hashizume, Yoshinobu Higuchi, Yasushi Uchiyama, et al.
Pageof 4